若生智能
Drug Database
AD

AD-220 (AD 220A / AD 220 / AD220)

✓ Approved

Addpharma · 小分子 · 小分子

什么是 AD-220？

AD-220 是一种小分子，由Addpharma研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

商品名AD 220A, AD 220, AD220
公司Addpharma
药物类别小分子
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Addpharma

治疗适应症

AD-220 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHyperlipidaemia✓ Approved
Metabolism and nutrition disordersHypercholesterolaemiaPreclinical

相关研究文献

PubMedBriefings in bioinformatics2026-07-27

Screening of cell-type-specific meta-programs for drug repurposing in Alzheimer's disease.

Zhang Chunlong C, Zhang Yuxi Y, Wu Zhiyi Z, Zhang Yuting Y et al.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder driven by complex cellular changes. To identify transcriptional signatures involved in AD pathology, we first analyzed nine single-cell/nucleus RNA-seq datasets from 67 high-pathology cases (Braak stages V/VI), generating an atlas of 363 243 cells. Using a multi-sample integration strategy, we identified 51 cross-sample meta-programs (MPs) across seven cell types that collectively capture key AD-related processes, including synaptic dysfunction and neuroinflammation. By screening bulk transcriptomes from 1208 ad and 725 normal samples, we found that 26 MPs (13 pathogenic and 13 protective) displayed differential activity in AD, characterized by up-regulation of microglia MPs and down-regulated of neuron MPs. Furthermore, spatial transcriptomics revealed that these MPs form spatially coherent communities associated with distinct cellular neighborhoods. Finally, we performed an integrative drug repurposing screen to identify candidate drugs predicted to regulate pathogenic MPs. In conclusion, we conducted an integrated multi-omics study to identify AD cell-type-specific MPs, and this framework can be applied to deconvolve cellular heterogeneity and screen candidate drugs for AD.

PMID 42506875
阅读全文 →
PubMedCells2026-07-27

Microglia in Alzheimer's Disease: From Homeostatic Guardians to Multifaceted Drivers of Neuropathology.

Ma Lizhen L, Zhao Yan Y, Cai Chaochan C, Liu Qing Q et al.

Background: Alzheimer's disease (AD) affects >55 million people worldwide and lacks disease-modifying therapies. Microglia, the CNS resident immune cells, dynamically transition between protective and pathological states during AD progression. Recent advances in single-cell sequencing and metabolomics reveal that microglial roles extend beyond simple M1/M2 polarization. This review synthesizes these advances into a framework integrating microglial plasticity, metabolic reprogramming, and intercellular communication in AD. Methods: We reviewed recent (2020-2026) studies on microglial biology in AD, focusing on DAM (disease-associated microglia) ontogeny, metabolic reprogramming, immune checkpoints, and glial crosstalk. Results: Microglia exhibit spatiotemporal heterogeneity, shifting from protective phagocytic phenotypes (M2, DAM1/2) in early AD to pro-inflammatory and exhausted states (M1, terminal inflammatory microglia [TIM], lipid droplet-accumulating microglia [LDAM]) as pathology advances. Key pathways-TREM2/SYK phagocytosis, Piezo1 mechanotransduction, TAM (Tyro3, Axl, Mer) receptor signaling, and metabolic regulators (HK2, iron, APOE4-driven lipid metabolism)-orchestrate these transitions. Microglia also interact with astrocytes, T cells, and peripheral immune cells via IL-3, complement C3, MHC-I and MHC-II, forming glial-immune networks that modulate Aβ clearance, tau propagation, and synaptic integrity. Conclusions: Precisely targeting microglial functional states, rather than broad immunosuppression, is a promising disease-modifying strategy for AD. Future therapies should integrate metabolic reprogramming, glial network regulation, and immune checkpoint modulation to preserve protective microglial phenotypes in early AD while suppressing pathological activation and exhaustion in advanced disease.

PMID 42505400
阅读全文 →
PubMedAlzheimer's & dementia : the journal of the Alzheimer's Association2026-07-27

The Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale in frontotemporal dementia and Alzheimer's disease.

Jiang Jessica J, Larsen Eva K EK, Levett Benjamin A BA, Core Lucy B LB et al.

Sleep disturbance is common in dementia, impacting daytime function and care. Compared with Alzheimer's disease (AD), sleep in frontotemporal dementia (FTD) is poorly characterized. We assessed sleep using the Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index in 58 people with primary progressive aphasia (PPA) and right temporal variant FTD, 32 with AD, and 36 cognitively healthy older volunteers. All participants had cognitive and behavioral assessments. Groups were compared using non-parametric statistics and correlations assessed sleep versus other indices. Subjective sleep duration was increased in all syndromic groups. AD and semantic PPA were associated with increased daytime somnolence. Reported sleep quality varied between syndromes. Across the disease cohort, somnolence correlated with behavioral and empathy deficits; in AD, poorer sleep quality correlated additionally with self-monitoring deficits. FTD and AD syndromes have distinct sleep phenotypes, and sleep alterations are associated with behavior. Standard sleep scales require careful interpretation in dementia.

PMID 42503587
阅读全文 →
PubMedDrug design, development and therapy2026-07-27

Deciphering the Multi-Target Therapeutic Mechanisms of Traditional Chinese Medicine Against Alzheimer's Disease: A Network Pharmacology Perspective.

Zhang Yiyi Y, Qin Gaofeng G, Lian Qinaqian Q, Sun Yuanyuan Y et al.

Alzheimer's disease (AD) poses a growing threat to global health, with no disease-modifying therapies currently available to cure or reverse its progression. Given its favorable safety profile and multi-target nature, Traditional Chinese Medicine (TCM) has attracted increasing attention as a potential strategy for AD prevention and treatment. In recent years, network pharmacology (NP) has emerged as a valuable predictive and analytical tool in TCM research, offering insights into the potential mechanisms underlying AD interventions. This review aims to systematically outline the methodology and commonly used databases in TCM NP, summarize the main TCM monomers and compounds studied for AD over the past decade, and identify five core signaling pathways, namely, the PI3K/Akt signaling pathway, the MAPK signaling pathway, the JAK-STAT signaling pathway, the AGE-RAGE signaling pathway, and the Nrf2 signaling pathway, implicated in pathogenesis and TCM action. To guide further exploration of TCM's role in AD management and to support subsequent research on its disease mechanisms and therapeutic strategies.

PMID 42504206
阅读全文 →
PubMedEuropean journal of dermatology : EJD2026-07-27

Novel insights into the role of microRNAs in atopic dermatitis and psoriasis: diagnostic and therapeutic aspects.

Yang Jiaqiang J, Wang Geng G, Zhang Yuanting Y, Zheng Rou R et al.

Atopic dermatitis (AD) and psoriasis are prevalent chronic inflammatory skin diseases with distinct clinical features and significant impacts on patients' quality of life. AD typically presents as recurrent eczema-like lesions accompanied by intense itching, whereas psoriasis is characterized by well-defined erythematous, scaly epidermal plaques. AD is associated with skin barrier dysfunction, allergen sensitization, and a type 2 immune response, while psoriasis involves hyperproliferation, abnormal differentiation of epidermal keratinocytes, and immune cell infiltration. However, the precise molecular mechanisms underlying AD and psoriasis remain unclear, posing challenges for effective clinical management. MicroRNAs (miRNAs) which are single-stranded RNA molecules that regulate gene expression post-transcriptionally by binding to target mRNAs, have been identified as key players in various inflammatory and immune- mediated skin diseases. In AD and psoriasis, miRNAs influence the progression of diseases by modulating inflammatory responses, keratinocyte hyperproliferation, and aberrant differentiation. Certain miRNAs hold promise as biomarkers for diagnosing and treating AD and psoriasis. This paper examines the roles of specific miRNAs in the pathogenesis of these conditions and provides a systematic overview of their diagnostic and therapeutic potential, offering new directions for clinical research and strategies. Advancements in miRNA research are expected to enhance diagnostic precision and support the development of targeted, personalized therapies, ultimately improving management of these complex dermatologic disorders.

PMID 42507399
阅读全文 →
PubMedCurrent psychiatry reports2026-07-27

Worry and Anxiety in the Era of Early Diagnosis and Disease Modifying Treatment for Alzheimer's Disease.

Stites Shana D SD, Lee Katherine K, Kuz Carolyn C, Mandell David D et al.

Psychologists and psychiatrists are well-positioned to be at the forefront of addressing the challenges posed by anxiety in early diagnosis and treatment of Alzheimer's disease (AD) dementia that are unfolding in primary care settings. The present article provides a summary of emerging areas in Alzheimer's disease testing and research to guide clinical decisions and research pursuits. The present article provides an overview of how anxiety is understood in early diagnosis of dementia due to AD, its influence in AD-related mechanisms, and the implications of these findings on current research practices. We conducted focused literature reviews between January and June 2026 and synthesized the information to provide a narrative review. Overall, the clinical roles of anxiety in AD dementia are expanding- from being viewed primarily as reactions to cognitive decline to serving as informative features of the diagnostic process and clinical course of the disease.

PMID 42507235
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多AD-220